Insmed to Present at Two October Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St futures rise ahead of jobs report as bond market steadies, oil slips
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- BofA's Hartnett sees risk-off mood lasting until dollar peaks
- Seagate and Western Digital shares fall on Toshiba HDD expansion
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Insmed (INSM) PT Raised to $35 at Credit Suisse Following FDA Approval of Arikayce
October 1, 2018 8:45 AM EDTCredit Suisse analyst Martin Auster raised the price target on Insmed (NASDAQ: INSM) to $35.00 (from $33.00) while maintaining a Outperform rating following an FDA announcement that it has approved Arikayce for the treatment of refractory NTM MAC, in line with the FDA AdCom... More
